At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 87 enrolled
Drug / intervention
insulin detemirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 20-week, Multi-centre, Open-labelled, Non-comparative Evaluation of the Safety and Efficacy of Insulin Detemir in Combination With Oral Anti-diabetic Drug(s), in Subjects With Type 2 Diabetes Mellitus Who Were Inadequately Controlled on Current Therapy in Korea
In Brief
A Phase 4 clinical trial evaluating insulin detemir for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 87 participants across 1 site.
Detailed Summary
This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type 2 diabetes mellitus in Korea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartNov 2007
Primary CompletionOct 2008
TodayJul 2026
First PostedApr 4, 2007
Enrollment StartNov 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.2 years ago
Interventions
insulin detemirdrug
Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).